Hao, J., Sun, L., Huang, H., Xiong, G., Liu, X., Qiu, L., Chen, G., Dong, B., Li, Y., Chen, W., Buechler, Y., Sun, J., Shen, C. and Luo, Q. Effects of Recombinant Human Interleukin 11 on Thrombocytopenia and Neutropenia in Irradiated Rhesus Monkeys. Radiat. Res. 162, 157–163 (2004).

The effects of recombinant human interleukin 11 (rhIL11) on thrombocytopenia and neutropenia in irradiated rhesus monkeys were evaluated after administration different doses at different times. Twenty-three rhesus monkeys were exposed to a total-body irradiation (TBI) with a single dose of 3 Gy 60Co γ rays. Either placebo, rhIL11 at a dose of 30, 60 or 120 μg/kg day−1 on days 0–13, or rhIL11 at a dose of 60 μg/kg day−1 on days 13–26 after TBI was administered to the animals. The results showed that the immediate treatment with rhIL11 but not treatment on days 13–26 resulted in much higher platelet nadirs than in the placebo-treated group. The accelerated recovery of platelets to normal levels after TBI was demonstrated in all groups treated with rhIL11, but the effects of rhIL11 were independent of dose. However, rhIL11 treatment could also accelerate the recovery of leukocytes to normal levels. The numbers of colony-forming bone marrow cells (CFU-E, CFU-Mix, CFU-MK and CFU-GM) in all groups treated with rhIL11 were increased 4- to 14-fold relative to those of the placebo group on day 30. We conclude that rhIL11 may directly promote megakaryocyte development and ameliorate myelosuppression in irradiated monkeys.

You do not currently have access to this content.